CliffBio
small molecule

LINZESS

LINACLOTIDE

Loss of exclusivityFebruary 2034latest FDA-listed patent expiry
CompanyAbbVie Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameLINZESS
Active ingredientLINACLOTIDE
Strength290MCG
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalAugust 2012
Marketing statusRX

Listed patents

PatentExpiresType
9708371*PEDFebruary 2034—
9708371August 2033product
8748573*PEDApril 2032—
8802628*PEDApril 2032—
8748573October 2031use U-1515
8802628October 2031product
8933030*PEDAugust 2031—
8933030February 2031product
7304036*PEDFebruary 2027—
7304036August 2026substance, product

More from AbbVie Inc.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

LINZESS patent cliff — loss of exclusivity February 2034 | CliffBio